Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ALT 110; Brain cancer vaccine - Celldex Therapeutics; CDX-110; PF-04948568; PF-04948569; PF-4948568; PF-4948569; Rindo; Rintega; SPX 110

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University; Johns Hopkins University
  • Developer Celldex Therapeutics Inc
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma; Solid tumours

Most Recent Events

  • 16 Oct 2017 Expanded access no longer available for rindopepimut in Glioblastoma (Recurrent, Second-line therapy or greater) (NCT03068650)
  • 08 Aug 2016 Discontinued - Phase-I for Solid tumours in USA (Intradermal)
  • 08 Aug 2016 Discontinued - Phase-II for Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (Intradermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top